Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
SAN DIEGO, July 26, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2017 financial results on Wednesday, August 9, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Wednesday, August 9, 2017 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | 60017665 |
| Live webcast: | Retrophin.com in the "Events & Presentations" section of the "Investors" page |
A replay of the call will be available from 7:30 p.m. ET, August 9, 2017 to 7:30 p.m. ET, August 16, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 60017665.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 (fosmetpantotenate) for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®.
Contact: Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 [email protected]
